Division of Vascular and Endovascular Surgery, Department of Surgery, Cardiovascular Research Institute, University of California, San Francisco CA 94117, United States.
Division of Vascular Surgery, Department of Surgery, The University of Tokyo, Bunkyo-City, Tokyo 113-8655, Japan.
Curr Drug Targets. 2018;19(11):1309-1317. doi: 10.2174/1389450118666171013101815.
Abdominal aortic aneurysms (AAA) are life-threatening because of the potential for rupture, resulting in death. The current standard treatment for AAA is surgery, comprising laparotomic graft replacement and endovascular repair. However, because surgery carries the risk of major complications and re-intervention, drug therapies are desirable because they may reduce the occurrence of enlargement and rupture.
Recent research shows that the progression of AAA is related to inflammatory reactions, especially those in the NF-κB pathway. Omega-3 polyunsaturated fatty acids (PUFA) show antiinflammatory effects. Some derivatives of omega-3 PUFA are known as specialized pro-resolving lipid mediators (SPM) such as resolvins. They play an important role in resolving inflammation.
Omega-3 PUFA and SPM may show promised effects for drug treatment of AAA.
由于破裂的潜在风险，腹主动脉瘤（AAA）是危及生命的。AAA 的当前标准治疗方法是手术，包括剖腹式移植物置换和血管内修复。然而，由于手术存在发生重大并发症和再次干预的风险，因此药物治疗是可取的，因为它们可能减少扩大和破裂的发生。
最近的研究表明，AAA 的进展与炎症反应有关，特别是 NF-κB 途径中的炎症反应。ω-3 多不饱和脂肪酸（PUFA）具有抗炎作用。一些 ω-3 PUFA 的衍生物被称为专门的促解决脂质介质（SPM），如 resolvins。它们在解决炎症中发挥重要作用。
ω-3 PUFA 和 SPM 可能对 AAA 的药物治疗显示出有希望的效果。
